387 related articles for article (PubMed ID: 16932955)
21. Apoptosis of HIV-specific CD8+ T cells: an HIV evasion strategy.
Petrovas C; Mueller YM; Katsikis PD
Cell Death Differ; 2005 Aug; 12 Suppl 1():859-70. PubMed ID: 15818412
[No Abstract] [Full Text] [Related]
22. Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy.
Lhomme E; Richert L; Moodie Z; Pasin C; Kalams SA; Morgan C; Self S; De Rosa SC; Thiébaut R
PLoS One; 2016; 11(4):e0152952. PubMed ID: 27124598
[TBL] [Abstract][Full Text] [Related]
23. CD8 T cell dysfunction during chronic viral infection.
Shin H; Wherry EJ
Curr Opin Immunol; 2007 Aug; 19(4):408-15. PubMed ID: 17656078
[TBL] [Abstract][Full Text] [Related]
24. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
[TBL] [Abstract][Full Text] [Related]
25. HIV vaccines: can CD4+ T cells be of help?
Van Braeckel E; Leroux-Roels G
Hum Vaccin Immunother; 2012 Dec; 8(12):1795-8. PubMed ID: 22906935
[TBL] [Abstract][Full Text] [Related]
26. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
[TBL] [Abstract][Full Text] [Related]
27. HLA-DR-restricted peptides identified in the Nef protein can induce HIV type 1-specific IL-2/IFN-gamma-secreting CD4+ and CD4+ /CD8+ T cells in humans after lipopeptide vaccination.
Gahery H; Figueiredo S; Texier C; Pouvelle-Moratille S; Ourth L; Igea C; Surenaud M; Guillet JG; Maillere B
AIDS Res Hum Retroviruses; 2007 Mar; 23(3):427-37. PubMed ID: 17411376
[TBL] [Abstract][Full Text] [Related]
28. Measuring HIV-1-specific T cell immunity: how valid are current assays?
D'Souza MP; Altfeld M
J Infect Dis; 2008 Feb; 197(3):337-9. PubMed ID: 18184092
[No Abstract] [Full Text] [Related]
29. Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients.
Chiacchio T; Petruccioli E; Vanini V; Cuzzi G; Pinnetti C; Sampaolesi A; Antinori A; Girardi E; Goletti D
J Infect; 2014 Dec; 69(6):533-45. PubMed ID: 24975174
[TBL] [Abstract][Full Text] [Related]
30. Differentiation of CD8 T cells in response to acute and chronic viral infections: implications for HIV vaccine development.
Miller JD; Masopust D; Wherry EJ; Kaech S; Silvestri G; Ahmed R
Curr Drug Targets Infect Disord; 2005 Jun; 5(2):121-9. PubMed ID: 15975018
[TBL] [Abstract][Full Text] [Related]
31. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine.
Gahery H; Daniel N; Charmeteau B; Ourth L; Jackson A; Andrieu M; Choppin J; Salmon D; Pialoux G; Guillet JG
AIDS Res Hum Retroviruses; 2006 Jul; 22(7):684-94. PubMed ID: 16831093
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.
Harrer T; Plettenberg A; Arastéh K; Van Lunzen J; Fätkenheuer G; Jaeger H; Janssens M; Burny W; Collard A; Roman F; Loeliger A; Koutsoukos M; Bourguignon P; Lavreys L; Voss G
Vaccine; 2014 May; 32(22):2657-65. PubMed ID: 24144472
[TBL] [Abstract][Full Text] [Related]
33. Vaccines. From Israel: a T-cell vaccine.
TreatmentUpdate; 2005; 17(1):11-2. PubMed ID: 17228460
[No Abstract] [Full Text] [Related]
34. [Current vaccination strategies].
Dietz K
Internist (Berl); 1992 Sep; 33(9):575-80. PubMed ID: 1399392
[No Abstract] [Full Text] [Related]
35. Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial.
Salmon-Céron D; Durier C; Desaint C; Cuzin L; Surenaud M; Hamouda NB; Lelièvre JD; Bonnet B; Pialoux G; Poizot-Martin I; Aboulker JP; Lévy Y; Launay O;
AIDS; 2010 Sep; 24(14):2211-23. PubMed ID: 20625264
[TBL] [Abstract][Full Text] [Related]
36. CD4+ and CD8+ T lymphocyte activation in HIV infection. Implications for immune pathogenesis and therapy.
Laurence J
Adv Exp Med Biol; 1995; 374():1-15. PubMed ID: 7572383
[No Abstract] [Full Text] [Related]
37. Memory CD8(+) T cells elicited by HIV-1 lipopeptide vaccines display similar phenotypic profiles but differences in term of magnitude and multifunctionality compared with FLU- or EBV-specific memory T cells in humans.
Figueiredo S; Charmeteau B; Surenaud M; Salmon D; Launay O; Guillet JG; Hosmalin A; Gahery H
Vaccine; 2014 Jan; 32(4):492-501. PubMed ID: 24291199
[TBL] [Abstract][Full Text] [Related]
38. Assessment of human CD4+ and CD8+ T lymphocyte responses in experimental viral vaccine studies.
Rothman AL; Yamada Y; Jameson J; Cruz J; West K; Green S; Ennis FA
Dev Biol Stand; 1998; 95():95-104. PubMed ID: 9855419
[TBL] [Abstract][Full Text] [Related]
39. Short communication: HIV antigen-specific reactivation of HIV infection from cellular reservoirs: implications in the settings of therapeutic vaccinations.
Shete A; Thakar M; Singh DP; Gangakhedkar R; Gaikwad A; Pawar J; Paranjape R
AIDS Res Hum Retroviruses; 2012 Aug; 28(8):835-43. PubMed ID: 21936714
[TBL] [Abstract][Full Text] [Related]
40. Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4 + and CD8 + T cell responses lasting more than seven years.
Lind A; Sommerfelt M; Holmberg JO; Baksaas I; Sørensen B; Kvale D
Scand J Infect Dis; 2012 Aug; 44(8):566-72. PubMed ID: 22339485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
